GLP1R and diabetic kidney disease: There are also the results of the first nephrological study using glucagon-like peptide-1 receptor agonists (GLP-1 RAs), FLOW, where the nephroprotective effect of semaglutide, administered subcutaneously to patients with DKD, was confirmed [14].